Cytox presents poster at AAIC 2019 on predicting an individual’s risk of developing Alzheimer's Disease
Poster shows how Cytox platform can genotype patients that are suitable for clinical trials
17th July 2019: Oxford & Manchester, UK. Cytox Ltd, which provides non-invasive, rapid, risk assessment and patient stratification tools for Alzheimer's disease and dementia, will make a poster presentation today at the Alzheimer's Association Internation Conference (AAIC 2019).
The poster (displayed from 9.30am at #P4-202) is titled: A Streamlined Integrated Process to Predict Genetic Risk of Alzheimer’s Disease. It shows how Cytox is able to predict an individual’s risk of developing Alzheimer’s Disease through its proprietary platform, as part of a streamlined integrated process, taking DNA from either a blood or saliva sample, through genotyping and Polygenic Risk Scoring (PRS) calculations to produce an estimation of risk of Alzheimer’s Disease. The development of such tools to identify disease risk is critical to enable selection of suitable individuals for inclusion into clinical trials and cohort studies.
Richard Pither, CEO of Cytox, said: “Our products, genoSCORETM and genoTORTM, provide highly valuable insight in to an individual’s risk of developing Alzheimer's Disease based on their genetics. These non-invasive tests, using either blood or saliva samples, allow developers of Alzheimer’s drugs to identify patients most suitable for clinical trials. Our products are now available on a fee-for-service basis, through a licensing agreement, or as part of a strategic partnership to develop companion diagnostics for future drugs.”
Please visit the Cytox AAIC booth in the conference exhibition hall (#202).